Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 3)
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
MONDAY, May 12, 2025 — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in th...
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 – Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 – Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...
2018 to 2022 Saw Increase in GLP-1 Receptor Agonist Use in Adults Without Diabetes
THURSDAY, April 10, 2025 – Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4 percent...
Biden Plan to Expand Obesity Drug Coverage Is Rejected
MONDAY, April 7, 2025 – The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden administration initiative that could have helped...
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
FRIDAY, April 4, 2025 – For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and...
Zepbound Now Available Through Hims & Hers
WEDNESDAY, April 2, 2025 – The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access...
GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions
TUESDAY, April 1, 2025 – The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. The number of people...
More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs
MONDAY, March 31, 2025 – Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 – The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the ...
No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia
THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome